Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM.

Lancet Haematol. 2018 Oct;5(10):e479-e492. doi: 10.1016/S2352-3026(18)30149-2.

PMID:
30290905
2.

Intestinal involvement in amyloidosis is a sequential process.

den Braber-Ymker M, Heijker S, Lammens M, Croockewit S, Nagtegaal ID.

Neurogastroenterol Motil. 2018 Dec;30(12):e13469. doi: 10.1111/nmo.13469. Epub 2018 Sep 19.

PMID:
30230124
3.

Analytical validation of the Hevylite assays for M-protein quantification.

Jacobs JFM, Haagen IA, Lodder A, van der Kroft C, de Kat Angelino CM, Croockewit S, Nieuwenhuys E, Gelderman KA.

Clin Chem Lab Med. 2018 Jun 27;56(7):1169-1175. doi: 10.1515/cclm-2017-0817.

PMID:
29397379
4.

Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods.

Jacobs JFM, de Kat Angelino CM, Brouwers HMLM, Croockewit SA, Joosten I, van der Molen RG.

Clin Chem Lab Med. 2018 Jan 26;56(2):312-322. doi: 10.1515/cclm-2017-0339.

PMID:
28771430
5.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P.

Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.

PMID:
28761118
6.

Predictors for successful PBSC collection on the fourth day of G-CSF-induced mobilization in allogeneic stem cell donors.

van Oostrum A, Zwaginga JJ, Croockewit S, Overdevest J, Fechter M, Ruiterkamp B, Brand A, Netelenbos T.

J Clin Apher. 2017 Dec;32(6):397-404. doi: 10.1002/jca.21528. Epub 2017 Jan 31.

PMID:
28139098
7.

Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.

Bol KF, van den Bosch T, Schreibelt G, Mensink HW, Keunen JE, Kiliç E, Japing WJ, Geul KW, Westdorp H, Boudewijns S, Croockewit SA, van Rossum MM, de Goede AL, Naus NC, van der Graaf WT, Gerritsen WR, de Klein A, Punt CJ, Figdor CG, Cohen VM, Paridaens D, de Vries IJ.

Ophthalmology. 2016 Oct;123(10):2265-7. doi: 10.1016/j.ophtha.2016.06.027. Epub 2016 Jul 29. No abstract available.

PMID:
27476772
8.

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.

Bol KF, Aarntzen EH, Pots JM, Olde Nordkamp MA, van de Rakt MW, Scharenborg NM, de Boer AJ, van Oorschot TG, Croockewit SA, Blokx WA, Oyen WJ, Boerman OC, Mus RD, van Rossum MM, van der Graaf CA, Punt CJ, Adema GJ, Figdor CG, de Vries IJ, Schreibelt G.

Cancer Immunol Immunother. 2016 Mar;65(3):327-39. doi: 10.1007/s00262-016-1796-7. Epub 2016 Feb 10.

9.

Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).

van de Donk NW, Otten HG, El Haddad O, Axel A, Sasser AK, Croockewit S, Jacobs JF.

Clin Chem Lab Med. 2016 Jun 1;54(6):1105-9. doi: 10.1515/cclm-2015-0888.

PMID:
26812873
10.

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.

Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Tel J, Winkels G, Petry K, Blokx WA, van Rossum MM, Welzen ME, Mus RD, Croockewit SA, Koornstra RH, Jacobs JF, Kelderman S, Blank CU, Gerritsen WR, Punt CJ, Figdor CG, de Vries IJ.

Clin Cancer Res. 2016 May 1;22(9):2155-66. doi: 10.1158/1078-0432.CCR-15-2205. Epub 2015 Dec 28.

11.

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients.

Bol KF, Figdor CG, Aarntzen EH, Welzen ME, van Rossum MM, Blokx WA, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Mus RD, Croockewit SA, Jacobs JF, Schuler G, Neyns B, Austyn JM, Punt CJ, Schreibelt G, de Vries IJ.

Oncoimmunology. 2015 Apr 1;4(8):e1019197. eCollection 2015 Aug.

12.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM.

Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585. Epub 2013 Aug 30.

13.

Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia.

Vos JM, Minnema MC, Wijermans PW, Croockewit S, Chamuleau ME, Pals ST, Klein SK, Delforge M, van Imhoff GW, Kersten MJ; HOVON Multiple Myeloma Working Party; HOVON Lymphoma Working Party.

Neth J Med. 2013 Mar;71(2):54-62.

14.

Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients.

Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, Boerman OC, Croockewit S, Oyen WJ, van Rossum M, Winkels G, Coulie PG, Punt CJ, Figdor CG, de Vries IJ.

Cancer Res. 2013 Feb 1;73(3):1063-75. doi: 10.1158/0008-5472.CAN-12-2583. Epub 2013 Jan 23.

15.

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.

Haroche J, Charlotte F, Arnaud L, von Deimling A, Hélias-Rodzewicz Z, Hervier B, Cohen-Aubart F, Launay D, Lesot A, Mokhtari K, Canioni D, Galmiche L, Rose C, Schmalzing M, Croockewit S, Kambouchner M, Copin MC, Fraitag S, Sahm F, Brousse N, Amoura Z, Donadieu J, Emile JF.

Blood. 2012 Sep 27;120(13):2700-3. Epub 2012 Aug 9.

16.

High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma.

Stevens-Kroef M, Weghuis DO, Croockewit S, Derksen L, Hooijer J, Elidrissi-Zaynoun N, Siepman A, Simons A, Kessel AG.

Genes Chromosomes Cancer. 2012 Nov;51(11):997-1006. doi: 10.1002/gcc.21982. Epub 2012 Jul 25.

PMID:
22833442
17.

Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.

Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG.

Clin Cancer Res. 2011 Sep 1;17(17):5725-35. doi: 10.1158/1078-0432.CCR-11-1261. Epub 2011 Jul 19.

18.

The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation.

Mohty M, Duarte RF, Croockewit S, Hübel K, Kvalheim G, Russell N.

Leukemia. 2011 Jan;25(1):1-6. doi: 10.1038/leu.2010.224. Review. No abstract available.

PMID:
21224858
19.

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.

Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, de Vries IJ, Punt CJ.

Cancer Immunol Immunother. 2011 Feb;60(2):249-60. doi: 10.1007/s00262-010-0942-x. Epub 2010 Nov 11.

PMID:
21069321
20.

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.

Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON).

Blood. 2010 Feb 11;115(6):1113-20. doi: 10.1182/blood-2009-05-222539. Epub 2009 Oct 30.

21.

Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma.

Lütje S, de Rooy JW, Croockewit S, Koedam E, Oyen WJ, Raymakers RA.

Ann Hematol. 2009 Dec;88(12):1161-8. doi: 10.1007/s00277-009-0829-0. Review.

22.

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.

Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreutz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Delforge M, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H; Dutch-Belgian HOVON; German GMMG.

Haematologica. 2008 Jan;93(1):124-7. doi: 10.3324/haematol.11644. Erratum in: Haematologica. 2008 Mar;93(3):480. Verhoef, Gregor [removed]; Delforge, Michel [added]; Breitkreuz, Iris [corrected to Breitkreutz, Iris].

23.

Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant.

Deegens JK, Andresdottir MB, Croockewit S, Wetzels JF.

Transpl Int. 2004 Mar;17(3):151-7.

PMID:
15101388
24.

Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.

de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ.

Clin Cancer Res. 2003 Nov 1;9(14):5091-100.

25.
26.

GM-CSF in haematopoietic stem cell transplantation.

Croockewit S.

Eur J Cancer. 1999 Aug;35 Suppl 3:S11-3. Review. No abstract available.

PMID:
10645214
27.
28.

Recurrent focal glomerulosclerosis: natural course and treatment with plasma exchange.

Andresdottir MB, Ajubi N, Croockewit S, Assmann KJ, Hibrands LB, Wetzels JF.

Nephrol Dial Transplant. 1999 Nov;14(11):2650-6.

PMID:
10534507
29.

Primitive multilineage progenitor cells predominate in peripheral blood early after mobilization with high-dose cyclophosphamide and GM-CSF or G-CSF.

Croockewit S, Raymakers R, Trilsbeek C, Dolstra H, Pennings A, de Witte T.

Leukemia. 1994 Dec;8(12):2194-9.

PMID:
7528861
30.

Fever in neutropenic patients treated with GM-CSF representing enhanced host defence.

Vreugdenhil G, Preyers F, Croockewit S, Sauerwein R, Swaak AJ, de Witte T.

Lancet. 1992 May 2;339(8801):1118-9. No abstract available.

PMID:
1349138

Supplemental Content

Loading ...
Support Center